MedDataX Logo

A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils

NCT ID: NCT02693769

Last Updated: 2016-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate whether fluticasone/formoterol Breath actuated inhaler is effective and well tolerated in the treatment of subjects with fixed airflow obstruction and elevated eosinophils.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is designed to provide efficacy and safety data for the use of fluticasone/formoterol Breath actuated inhaler in subjects with the characteristics of fixed airflow obstruction and elevated eosinophils. These patients have typically been excluded from previous Flutiform pMDI asthma and chronic obstructive pulmonary disease (COPD) trials; for example in asthma studies, patients with a smoking history of 10 pack years or more have been excluded, conversely in COPD studies patients with any prior history of asthma have been excluded. It is expected that the data from this study will provide a greater understanding of the effects of fluticasone/formoterol in this patient population

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

fluticasone/formoterol BAI

To compare the efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.)

Group Type EXPERIMENTAL

fluticasone propionate/formoterol fumarate breath actuated inhaler

Intervention Type DRUG

Indacaterol maleate / glycopyrronium bromide capsules

Intervention Type DRUG

Ultibro Breezhaler

Ultibro Breezhaler 85/43 µg (1 puff o.d.)

Group Type ACTIVE_COMPARATOR

fluticasone propionate/formoterol fumarate breath actuated inhaler

Intervention Type DRUG

Indacaterol maleate / glycopyrronium bromide capsules

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluticasone propionate/formoterol fumarate breath actuated inhaler

Intervention Type DRUG

Indacaterol maleate / glycopyrronium bromide capsules

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects aged ≥ 40 years at Screening visit.
2. Adequate contraception:
3. Diagnosis of fixed airflow obstruction with elevated eosinophils
4. Subjects symptomatic at Visit 1 (CAT ≥10) despite currently receiving treatment with either LAMA or LABA monotherapy or LAMA + LABA as a combination inhaler or separate inhalers.
5. Documented history of ≥ 1 moderate or severe respiratory disease exacerbations (requiring treatment with systemic corticosteroids and/or antibiotics and/or hospitalisation) in the previous year.
6. Willing and able to replace current therapy for obstructive lung disease with study medication.
7. Able to demonstrate correct use of a BAI, Breezehaler and pMDI.

Exclusion Criteria

1. Respiratory disease exacerbation between 4 weeks prior to screening and Visit 3 (Randomisation).
2. Previous treatment with ICS.
3. Documented evidence of α1-antitrypsin deficiency.
4. Other active respiratory disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung disease, cystic fibrosis, bronchiolitis obliterans.
5. Use of long-term oxygen therapy (LTOT) at least 12 hours daily or mechanical ventilation.
6. Chest X-ray or CT scans performed prior to screening which reveal evidence of clinically significant abnormalities reflective of active disease not believed to be due to COPD
7. Evidence of uncontrolled cardiovascular disease.
8. Evidence of clinically significant renal, hepatic, gastrointestinal, or psychiatric disease.
9. Current malignancy or a previous history of cancer which has been in remission for \< 5 years (basal cell or squamous cell carcinoma of the skin which has been resected is not excluded).
10. Clinically significant sleep apnoea requiring use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.
11. Participation in the acute phase of a pulmonary rehabilitation programme within 4 weeks prior to screening or during the study.
12. Known or suspected history of drug or alcohol abuse in the last 2 years.
13. Requiring treatment with any of the prohibited concomitant medications.
14. Known or suspected hypersensitivity or contraindication to any of the study drugs or excipients.
15. Received an investigational drug within 30 days of the Screening.
16. Received a systemic corticosteroid within 30 days of the Screening visit.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mundipharma Research Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

JURMED, s.r.o.

Košice, , Slovakia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Slovakia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KFL3503

Identifier Type: -

Identifier Source: org_study_id